Redwire Secures $4M Funding from NASA for Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 hours ago
0mins
Should l Buy RDW?
Source: Benzinga
- Funding Support: NASA has awarded Redwire $4 million to support its new drug development initiatives, which significantly enhances Redwire's role in space and defense technology solutions and may lead to major advancements in drug development processes.
- Market Performance: Amid a mixed market day, Redwire shares rose by 0.98% to $9.35, indicating positive sentiment in the technology sector, with the stock trading above both its 20-day and 100-day simple moving averages, suggesting short-term strength.
- Financial Snapshot: Last month, Redwire reported a loss of 58 cents per share, missing the consensus estimate of a 19-cent loss, but revenue totaled $108.79 million, exceeding the expected $102.36 million, showcasing the company's potential for revenue growth.
- Analyst Ratings: Redwire carries a Buy rating with an average price target of $11.75, and recent analyst actions, including Truist Securities raising its target to $15, reflect market confidence in the company's growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RDW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RDW
Wall Street analysts forecast RDW stock price to rise
9 Analyst Rating
6 Buy
2 Hold
1 Sell
Moderate Buy
Current: 9.230
Low
6.00
Averages
12.50
High
22.00
Current: 9.230
Low
6.00
Averages
12.50
High
22.00
About RDW
Redwire Corporation is an integrated aerospace and defense company focused on advanced technologies. The Company is focused on aerospace infrastructure, autonomous systems and multi-domain operations leveraging digital engineering and AI automation. Its capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, microgravity payloads and uncrewed airborne system (UAS) technology. It specializes in core avionics, such as scalable power distribution and on-board computing capabilities. These specialized avionics and sensors can be applied across multiple space environments, including Low Earth Orbit, Geostationary Orbit, Cis-lunar and deep space missions. It provides a range of sensors, including star trackers and sun sensors, which are critical for navigation and control of spacecraft. It offers a variety of solar array solutions for spacecraft spanning the spectrum of size, power needs, and orbital location.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Redwire Secures Additional $4 Million from NASA for Drug Development
- Funding Expansion: NASA has awarded Redwire an additional $4 million to support new drug development investigations on the ISS, expanding an existing $25 million contract, which underscores NASA's trust and commitment to Redwire's technology.
- Technological Innovation: Redwire's Pharmaceutical In-space Laboratory (PIL-BOX) technology has successfully flown 43 units, contributing to the growth of high-quality crystals that could revolutionize the development of lifesaving medicines, enhancing the company's competitive edge in biotechnology.
- Partnerships: Redwire is collaborating with several biotech firms, including Aspera Biomedicines, to advance the development of Rebecsinib using PIL-BOX, with research results potentially offering broader cancer treatment options, thereby solidifying its leadership position in the biopharmaceutical sector.
- Industry Transformation: By partnering with NASA, Redwire is driving the convergence of the space and pharmaceutical industries, leveraging microgravity to unlock new insights aimed at improving treatments for diseases like cancer, osteoporosis, and obesity, highlighting its strategic significance in the future of biotechnology.
See More
Redwire Secures $4M Funding from NASA for Drug Development
- Funding Support: NASA has awarded Redwire $4 million to support its new drug development initiatives, which significantly enhances Redwire's role in space and defense technology solutions and may lead to major advancements in drug development processes.
- Market Performance: Amid a mixed market day, Redwire shares rose by 0.98% to $9.35, indicating positive sentiment in the technology sector, with the stock trading above both its 20-day and 100-day simple moving averages, suggesting short-term strength.
- Financial Snapshot: Last month, Redwire reported a loss of 58 cents per share, missing the consensus estimate of a 19-cent loss, but revenue totaled $108.79 million, exceeding the expected $102.36 million, showcasing the company's potential for revenue growth.
- Analyst Ratings: Redwire carries a Buy rating with an average price target of $11.75, and recent analyst actions, including Truist Securities raising its target to $15, reflect market confidence in the company's growth prospects.
See More
Redwire Secures Additional $4 Million from NASA for Drug Development
- Increased Funding: Redwire has secured an additional $4 million from NASA to support new drug development investigations using its Pharmaceutical In-space Laboratory (PIL-BOX) technology on the ISS, expanding an existing $25 million contract, which underscores NASA's confidence in the technology.
- Significant Technical Impact: With 43 units flown, PIL-BOX has facilitated the growth of high-quality crystals, a breakthrough that could revolutionize the development of lifesaving medicines, enhancing Redwire's competitive edge in the aerospace pharmaceutical sector.
- Cancer Treatment Research Collaboration: Redwire is collaborating with Aspera Biomedicines to utilize PIL-BOX for cancer therapy research, particularly in the development of rebecsinib, with results potentially offering broader treatment options for cancer patients, thereby increasing the company's market influence.
- Future Growth Potential: This funding not only provides robust support for Redwire's drug development but also lays the groundwork for business growth in 2026, indicating the company's long-term strategic positioning in the aerospace pharmaceutical research field.
See More
Redwire Secures Additional $4 Million from NASA for Drug Development
- Funding Expansion: NASA has awarded Redwire an additional $4 million to support new drug development investigations on the ISS, expanding an existing $25 million contract, which underscores NASA's trust and commitment to Redwire's innovative technology.
- Technology Application: Redwire's Pharmaceutical In-space Laboratory (PIL-BOX) technology has successfully flown 43 units, contributing to the growth of high-quality crystals that could revolutionize the development of lifesaving medicines, presenting significant commercial potential.
- Collaborative Projects: Recently, Redwire supported a cancer therapy investigation led by Aspera Biomedicines, utilizing PIL-BOX to advance the development of Rebecsinib, with results potentially offering broader cancer treatment options, highlighting the promising applications of microgravity in biotechnology.
- Industry Transformation: By collaborating with partners such as Aspera, Bristol Myers Squibb, and Eli Lilly, Redwire is driving a new era in biotechnology, leveraging microgravity to unlock insights that can enhance treatment options for some of the world's most challenging diseases, which has profound societal implications.
See More
Redwire Corporation Stock Soars on Upgrade
- Analyst Upgrade: Truist Securities analyst Michael Ciamoli upgraded Redwire stock to 'buy' with a $15 price target, indicating a potential 66% upside, reflecting growing market confidence in the company's future prospects.
- Profitability Outlook: Ciamoli forecasts gross margins to rise from 9.2% in 2025 to 23.3% in 2026, which not only indicates the acceleration of Redwire's programs but also suggests potential reductions in future R&D costs, thereby improving overall financial health.
- Operating Cost Challenges: Despite the expected margin improvements, Redwire's operating costs consumed 57% of revenue in 2025, indicating that even with a 23.3% gross margin, profitability remains elusive, highlighting the company's struggles on the path to profitability.
- Cash Flow Prospects: Analysts predict that Redwire may achieve positive free cash flow by 2027, providing investors with a more substantial basis for valuation, and combined with the current sales multiple, the stock's attractiveness is further enhanced.
See More
Truist Analyst Upgrades Redwire to Buy with $15 Target
- Rating Upgrade: Truist analyst Michael Ciamoli upgraded Redwire's stock to 'buy' with a price target of $15, indicating a potential 66% upside, reflecting market optimism about the company's future growth prospects.
- Margin Forecast: Ciamoli predicts that Redwire's gross profit margins could surge from 9.2% in 2025 to 23.3% in 2026, which would significantly improve the company's financial health, although current operating costs still consume 57% of revenue.
- Cash Flow Outlook: Analysts suggest that Redwire may achieve positive free cash flow for the first time in 2027, providing investors with a more attractive valuation basis, especially against the backdrop of current revenue growth.
- Market Appeal: With the stock trading at three times sales, Redwire is starting to look attractive, and the upcoming catalyst of positive cash flow may draw more investor interest towards the stock.
See More
Redwire Secures Additional $4 Million from NASA for Drug Development
- Funding Expansion: NASA has awarded Redwire an additional $4 million to support new drug development investigations on the ISS, expanding an existing $25 million contract, which underscores NASA's trust and commitment to Redwire's technology.
- Technological Innovation: Redwire's Pharmaceutical In-space Laboratory (PIL-BOX) technology has successfully flown 43 units, contributing to the growth of high-quality crystals that could revolutionize the development of lifesaving medicines, enhancing the company's competitive edge in biotechnology.
- Partnerships: Redwire is collaborating with several biotech firms, including Aspera Biomedicines, to advance the development of Rebecsinib using PIL-BOX, with research results potentially offering broader cancer treatment options, thereby solidifying its leadership position in the biopharmaceutical sector.
- Industry Transformation: By partnering with NASA, Redwire is driving the convergence of the space and pharmaceutical industries, leveraging microgravity to unlock new insights aimed at improving treatments for diseases like cancer, osteoporosis, and obesity, highlighting its strategic significance in the future of biotechnology.
See More
Redwire Secures $4M Funding from NASA for Drug Development
- Funding Support: NASA has awarded Redwire $4 million to support its new drug development initiatives, which significantly enhances Redwire's role in space and defense technology solutions and may lead to major advancements in drug development processes.
- Market Performance: Amid a mixed market day, Redwire shares rose by 0.98% to $9.35, indicating positive sentiment in the technology sector, with the stock trading above both its 20-day and 100-day simple moving averages, suggesting short-term strength.
- Financial Snapshot: Last month, Redwire reported a loss of 58 cents per share, missing the consensus estimate of a 19-cent loss, but revenue totaled $108.79 million, exceeding the expected $102.36 million, showcasing the company's potential for revenue growth.
- Analyst Ratings: Redwire carries a Buy rating with an average price target of $11.75, and recent analyst actions, including Truist Securities raising its target to $15, reflect market confidence in the company's growth prospects.
See More
Redwire Secures Additional $4 Million from NASA for Drug Development
- Increased Funding: Redwire has secured an additional $4 million from NASA to support new drug development investigations using its Pharmaceutical In-space Laboratory (PIL-BOX) technology on the ISS, expanding an existing $25 million contract, which underscores NASA's confidence in the technology.
- Significant Technical Impact: With 43 units flown, PIL-BOX has facilitated the growth of high-quality crystals, a breakthrough that could revolutionize the development of lifesaving medicines, enhancing Redwire's competitive edge in the aerospace pharmaceutical sector.
- Cancer Treatment Research Collaboration: Redwire is collaborating with Aspera Biomedicines to utilize PIL-BOX for cancer therapy research, particularly in the development of rebecsinib, with results potentially offering broader treatment options for cancer patients, thereby increasing the company's market influence.
- Future Growth Potential: This funding not only provides robust support for Redwire's drug development but also lays the groundwork for business growth in 2026, indicating the company's long-term strategic positioning in the aerospace pharmaceutical research field.
See More
Redwire Secures Additional $4 Million from NASA for Drug Development
- Funding Expansion: NASA has awarded Redwire an additional $4 million to support new drug development investigations on the ISS, expanding an existing $25 million contract, which underscores NASA's trust and commitment to Redwire's innovative technology.
- Technology Application: Redwire's Pharmaceutical In-space Laboratory (PIL-BOX) technology has successfully flown 43 units, contributing to the growth of high-quality crystals that could revolutionize the development of lifesaving medicines, presenting significant commercial potential.
- Collaborative Projects: Recently, Redwire supported a cancer therapy investigation led by Aspera Biomedicines, utilizing PIL-BOX to advance the development of Rebecsinib, with results potentially offering broader cancer treatment options, highlighting the promising applications of microgravity in biotechnology.
- Industry Transformation: By collaborating with partners such as Aspera, Bristol Myers Squibb, and Eli Lilly, Redwire is driving a new era in biotechnology, leveraging microgravity to unlock insights that can enhance treatment options for some of the world's most challenging diseases, which has profound societal implications.
See More
Redwire Corporation Stock Soars on Upgrade
- Analyst Upgrade: Truist Securities analyst Michael Ciamoli upgraded Redwire stock to 'buy' with a $15 price target, indicating a potential 66% upside, reflecting growing market confidence in the company's future prospects.
- Profitability Outlook: Ciamoli forecasts gross margins to rise from 9.2% in 2025 to 23.3% in 2026, which not only indicates the acceleration of Redwire's programs but also suggests potential reductions in future R&D costs, thereby improving overall financial health.
- Operating Cost Challenges: Despite the expected margin improvements, Redwire's operating costs consumed 57% of revenue in 2025, indicating that even with a 23.3% gross margin, profitability remains elusive, highlighting the company's struggles on the path to profitability.
- Cash Flow Prospects: Analysts predict that Redwire may achieve positive free cash flow by 2027, providing investors with a more substantial basis for valuation, and combined with the current sales multiple, the stock's attractiveness is further enhanced.
See More
Truist Analyst Upgrades Redwire to Buy with $15 Target
- Rating Upgrade: Truist analyst Michael Ciamoli upgraded Redwire's stock to 'buy' with a price target of $15, indicating a potential 66% upside, reflecting market optimism about the company's future growth prospects.
- Margin Forecast: Ciamoli predicts that Redwire's gross profit margins could surge from 9.2% in 2025 to 23.3% in 2026, which would significantly improve the company's financial health, although current operating costs still consume 57% of revenue.
- Cash Flow Outlook: Analysts suggest that Redwire may achieve positive free cash flow for the first time in 2027, providing investors with a more attractive valuation basis, especially against the backdrop of current revenue growth.
- Market Appeal: With the stock trading at three times sales, Redwire is starting to look attractive, and the upcoming catalyst of positive cash flow may draw more investor interest towards the stock.
See More
